Downloads
-
A New Tool For Rapid Analysis Of Large Viral Vectors
4/25/2024
Optimize your viral vector characterization with an instrument that features a semiautomatic workflow, enabling you to analyze samples of adenovirus and lentivirus within minutes.
-
Benchtop Macro Mass Photometer: KaritroMP
4/25/2024
The new KaritroMP is a benchtop instrument that characterizes large viral vectors. Ideal for informing process development in preclinical settings and early drug development, it analyzes samples of adenovirus vectors (AdV) and lentivirus vectors (LVV) in just minutes. The instrument offers essential vector analysis capabilities, including the assessment of sample purity and stability.
-
Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles
4/25/2024
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?
-
AAV Analytics: Key Considerations When Developing A Clinical Program
4/25/2024
Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.
-
Integrating Quality Processes And Documentation After A Merger
4/25/2024
If your company is undergoing a merger, you must juggle operations while ensuring minimal disruptions. You'll need a holistic view of QMS and SOPs to harmonize procedures.
-
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
4/25/2024
BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months.
-
Bulk Filling Of Drug Substance | Accurate Aliquoting
4/24/2024
Bulk filling drug substances in traditional facilities is often a lengthy, manual process where operators are relied upon to adjust pump controls to achieve accurate filling. This method, spanning multiple shifts, increases process risk through errors that can compromise accuracy.
-
Clone, Strain, And Viral Construct Screening Executed For You
4/24/2024
Evaluate your clones, strains, and viral constructs in our bioreactors with flexible scale out.
Benefits
Select the best clone by evaluating larger experimental cohorts
Make the most informed, data-driven selection by leveraging our fleet of 250mL and 5L Culture bioreactors to screen your clones, strains and viral constructs.
Defer your capital equipment spend
Evaluate your clones, strains and viral constructs without the need for new capital equipment.
Transparent, real-time data provided by a team of experts
Painless technology transfer with live data relayed via our cloud-connected systems. We have >95% success rate with >22,000 runs successfully executed.
-
Leverage Bioreactor Capacity When You Need It With Culture Bioreactors
4/24/2024
Gain access to Culture bioreactors when you need rapid overflow experimental capacity.
Benefits
Progress studies faster
Run overflow projects and conduct parallel experiments with Culture to reduce time and alleviate bottlenecks.
Stay agile in your capacity planning
Scale your workload at Culture according to your current needs. Respond rapidly to surging demands.
Eliminate your capital equipment spend
Leverage Culture’s facility quickly to avoid building out lab space, spending capital on equipment, and hiring specialized staff.
-
Streamlining Single-Use Assemblies In The Bulk-Fill Step Of Downstream Processing
4/24/2024
Single-use (SU) systems and components are growing in demand as they offer minimal contamination risk. Review a standardized SU assembly for bulk-fill processing that aims to improve efficiency.